Media.Player

Inhibitors for the Treatment of T Cell-Mediated Autoimmune Disorders

Technology Benefits

This drug may be more effective in treating T-cell mediated diseases than other currently marketed immunosuppressants This drug can be administered orally, subcutaneously, intramuscularly, or intravenously, alone, or in combination with other drugs Can be used as an alternative treatment in patients who cannot tolerate the severe side effects of currently marketed immunosuppressive drugs Can be used to treat autoimmune diseases or graft-versus-host disease in patients who underwent immunosuppressive drug treatments that did not produce desirable effects

Technology Application

Therapeutic immunosuppressant in humans and animals Treat a broad range of T-cell mediated autoimmune disorders and chronic-graft-versus host disease including: multiple sclerosis, rheumatoid arthritis, type-1 diabetes, psoriasis, and chronic graft-versus-host disease in humans and animals

Detailed Technology Description

T lymphocytes (T cells) play a critical role in regulation of immune system function. They control cell-mediated immunity, provide defense against infectious microbes, recognize and eliminate foreign substances, and act as surveillance for cancer cells. T cells, however, are also the primary causes of inflammatory responses in patients with autoimmune disorders and graft rejection in organ transplant patients. Researchers at the University of California, Davis have discovered that Dantrolene, a FDA approved drug currently used for the treatment of muscular skeletal dysfunctions, significantly suppresses CD4+ T cell functions such as proliferation and cytokine production. By targeting T cells, Dantrolene can effectively reduce inflammation-induced tissue damage. Furthermore, this drug can effectively reduce graft rejection.

Supplementary Information

Patent Number: US8664251B1
Application Number: US2010727865A
Inventor: Fomina, Alla F.
Priority Date: 26 Feb 2009
Priority Number: US8664251B1
Application Date: 19 Mar 2010
Publication Date: 4 Mar 2014
IPC Current: A01N004350 | A01N004308 | A61K003134 | A61K0031415
US Class: 514390 | 514461
Assignee Applicant: The Regents of the University of California
Title: Ryanodine receptor inhibitors for treatment of T-cell mediated disorders
Usefulness: Ryanodine receptor inhibitors for treatment of T-cell mediated disorders
Summary: The method is useful for: treating or preventing the progression of multiple sclerosis and a T cell-mediated disorder such as graft-versus-host disease and rheumatoid arthritis in a patient, preferably a human (all claimed); and treating autoimmune diseases including myasthenia gravis, autoimmune neuropathies such as Guillain-Barre, autoimmune uveitis, autoimmune hemolytic anemia, pernicious anemia, autoimmune thrombocytopenia, temporal arteritis, anti-phospholipid syndrome, vasculitides such as Wegener's granulomatosis, Behcet's disease, atherosclerosis, psoriasis, dermatitis herpetiformis, pemphigus vulgaris, vitiligo, mycosis fungoides, allergic contact dermatitis, atopic dermatitis, lichen planus, Crohn's disease, ulcerative colitis, primary biliary cirrhosis, autoimmune hepatitis, type 1 diabetes mellitus, Addison's disease, Grave's disease, Hashimoto's thyroiditis, autoimmune oophoritis and orchitis, autoimmune thyroiditis, systemic lupus erythematosus, scleroderma, polymyositis, dermatomyositis, spondyloarthropathies such as ankylosing spondylitis, and Sjogren's Syndrome. Test details are described but no results given.
Novelty: Treating or preventing progression of multiple sclerosis in patient not suffering from debilitating spasticity, involves administering composition comprising dantrolene, and carrier

Industry

Disease Diagnostic/Treatment

Sub Category

Other Disease

Application No.

8664251

Others

Tech ID/UC Case

11171/2009-313-0

Related Cases

2009-313-0

*Abstract

Method of using Dantrolene, a FDA-approved drug, currently used for treatment of muscular skeletal dysfunction, to treat T-lymphocyte mediated disorders (autoimmune diseases and chronic graft versus host disease) in humans and animals.

*IP Issue Date

Mar 4, 2014

*Principal Investigator

Name: Alla Fomina

Department:

Country/Region

USA